The stock of NovoCure Limited (NASDAQ:NVCR) decreased by -$11.17 on Monday to finish at $18.60, down -37.50 percent. The last five days have seen an average of 3,401,180 shares of common stock traded. 2 times new highs were reached in the current year, with a fall of -$54.74. The average number of shares traded over the last 20 days was 1,955,160, while the average volume over the last 50 days totaled 1,547,524.
NVCR stock dropped -44.16% since last month. On 08/28/23, the company’s shares reached a one-month low of $18.60. The stock touched a high of $120.03 on 01/05/23, after rallying from a low of $26.68 in 52 weeks. The price of NVCR stock has declined by -74.64% or -$54.74 this year, reaching a new high 2 times. Still, the stock price is down -84.50% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
NVCR stock investors should be aware that NovoCure Limited (NVCR) stock had its last reported insider trading activity 27 days ago on Aug 02. On Aug 02, Chief Financial Officer Cordova Ashley sold 1,144 shares at $30.25 each. This transaction resulted in the insider making $34,607. On Mar 07, Leonard Frank X sold 8,318 shares at a price of US$75.16. After the transaction, the insider now owns 54,284 shares. Chief Operating Officer GROENHUYSEN WILHELMUS CM had earlier sold 25,635 shares on Mar 03 for $76.16 a share. The transaction was completed for $1,952,346.
Valuation Metrics
Beta for the stock is 0.58. There are also a few other valuation ratios worth considering, including the trailing price-to-sales (P/S) ratio of 3.94, the price-to-book (PB) ratio of 4.76.
Financial Health
For the three months ended June 29, NovoCure Limited’s quick ratio was 6.90, while its current ratio was 7.10, indicating its ability to pay off its debt. The company’s long-term debt to equity ratio for the quarter ending June 29 is 1.36, and the total debt to equity ratio is 1.36. As far as profitability goes, gross margin for the trailing twelve months is 75.90% percent. NovoCure Limited’s EBITDA margin for the year ended June 29 was -14.56%, whereas its operating margin stood at -37.50% for the same period. Based on annual data, it had gross profit of $422.97 million and revenue of $537.84 million.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. NVCR’s return on assets (ROA) during the last 12 months has been -14.80%. There was a -10.00% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was -40.20%.
Earnings Surprise
According to NovoCure Limited’s quarterly financial report for the quarter that ended June 29. A higher net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $126.05 million, while revenues fell by -11.76% to $122.18 million. It was predicted that NovoCure Limited’s quarterly earnings would be -$0.54, but it ended up being -$0.5, beating the consensus by -8.00%. EBITDA was -$65.01 million for the quarter. At the end of NovoCure Limited’s most recent quarter ended June 29, its liabilities totaled 743.33 million, while its total debt was $587.48 million. Equity owned by shareholders amounts to $106.62 million.
Technical Picture
Here’s a quick look at NovoCure Limited’s (NVCR) price momentum from a technical perspective. As of 28 August, the RSI 9-day stood at 10.50%, suggesting the stock is oversold, with a 228.13% historical volatility rate.
The stochastic %K and %D were 41.24% and 55.47% respectively, while the average true range (ATR) was 2.46. Based on the 14-day stochastic reading of 0.04%, the RSI (14) reading is 15.93%. On the 9-day MACD Oscillator, the stock is at -3.10, and the 14-day reading is at -3.65.
Analyst Ratings
NovoCure Limited (NASDAQ: NVCR) was downgraded by H.C. Wainwright to a a Neutral rating in its latest research report. The stock was previously rated as a a Buy. Analysts have assigned NovoCure Limited (NVCR) an Overweight rating. NVCR is a stock that is recommended for selling by 0 brokerage firms, while 3 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 0 rates it overweight and 3 others recommend it as a buy.
What is NVCR’s price target for the next 12 months?
The current consensus forecast for the stock is between $23.00 and $49.00, with a median target price of $34.00. In analyzing these forecasts, the average price target given by analysts for NovoCure Limited (NVCR) is $35.17.
